Atea Pharmaceuticals Stock (NASDAQ:AVIR)


ForecastOwnershipFinancialsChartTranscripts

Previous Close

$3.29

52W Range

$2.77 - $4.60

50D Avg

$3.58

200D Avg

$3.74

Market Cap

$282.81M

Avg Vol (3M)

$194.03K

Beta

0.17

Div Yield

-

AVIR Company Profile


Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

75

IPO Date

Oct 30, 2020

Website

AVIR Performance


AVIR Financial Summary


Dec 23Dec 22Dec 21
Revenue--$351.37M
Operating Income$-164.16M$-130.65M$138.38M
Net Income$-135.96M$-115.91M$121.19M
EBITDA$-163.75M$-130.65M$138.38M
Basic EPS$-1.63$-5.37$1.46
Diluted EPS$-1.63$-5.37$1.37

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 11, 24 | 12:13 PM
Q1 24May 14, 24 | 12:00 AM
Q4 23Feb 28, 24 | 11:24 PM

Peer Comparison


TickerCompany
CNSPCNS Pharmaceuticals, Inc.
CWBRCohBar, Inc.
AVROAVROBIO, Inc.
EFTReFFECTOR Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
OCEAOcean Biomedical, Inc.
HEPAHepion Pharmaceuticals, Inc.
ELEVElevation Oncology, Inc.
ENVBEnveric Biosciences, Inc.